Patent application number | Description | Published |
20080234289 | Melanocortin Receptor-Specific Compounds - A melanocortin receptor-specific compound of the general formula of structure I: | 09-25-2008 |
20080255033 | Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds - Metallopeptides with a sequence of a biologically active gamma-melanocyte stimulating hormone sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the three position to the n position, with a metal ion complexed thereto, with any proline (Pro) residue which is either of the two residues on the immediately adjacent N-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog. | 10-16-2008 |
20090069224 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics - Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I: | 03-12-2009 |
20090076029 | Compounds and Methods for Treating Obesity - Methods for selection of compounds for treatment of obesity, compounds selected by the disclosed methods, and methods of treatment of obesity, wherein a selective melanocortin-4 receptor compound is identified, which compound is further characterized in that it attenuates the binding of both an agonist, including alpha-melanocyte stimulating hormone, and an inverse agonist, including agouti-related protein, to a melanocortin receptor, including melanocortin-4 receptor. | 03-19-2009 |
20090081197 | Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity - Provided are methods for selecting melanocortin receptor-specific compounds for attenuating food intake and for treatment of specific disease conditions, including treatment of obesity and related energy homeostasis or feeding disorders characterized by excess weight gain, without inducing a sexual response, and methods for selecting compounds for treatment of sexual dysfunction. Further provided are pharmaceutical preparations defined by such methods, and methods and preparations for attenuating food intake and treatment of said conditions. | 03-26-2009 |
20090305960 | Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669 - Melanocortin receptor-specific cyclic peptides of the formula | 12-10-2009 |
20100035821 | Amide Linkage Cyclic Natriuretic Peptide Constructs - Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: | 02-11-2010 |
20100075895 | Cyclic Natriuretic Peptide Constructs - Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: | 03-25-2010 |
20110009341 | N-Alkylated Cyclic Peptide Melanocortin Agonists - A melanocortin-4 receptor agonist cyclic peptide of the formula | 01-13-2011 |
20110263818 | Peptidic Constructs with Amino Acid Surrogates - Peptidic constructs including at least one ring-constrained amino acid surrogate of formula I: | 10-27-2011 |
20120178701 | Melanocortin Receptor-Specific Peptides - Melanocortin receptor-specific cyclic peptides of the formula | 07-12-2012 |
20140357575 | Melanocortin Receptor-Specific Heptapeptides - Melanocortin receptor-specific cyclic heptapeptides of the formula | 12-04-2014 |